Approval marks milestone for AI use in frontline care
Category: News
New therapy offers hope for patients with limited option
Study paves the way for personalised therapies for osteoarthritis sufferer
CHMP recommendation brings new hope for patients
VYVGART could be the first CIDP drug with a novel mechanism in 30 years
Cambridge firm in-licenses two oncology programmes
MHRA authorises drug for adults with rare heart muscle damage
It is hoped that the MAGIC-I study will support earlier diagnosis and personalised treatment
The university has been awarded a £1m grant from LifeArc and Muscular Dystrophy UK
The SHIELD-Utah study compared Novavax’s vaccine to the Pfizer/BioNTech mRNA 2024-2025 vaccine